Drug profile · INN
donanemab-azbt
KISUNLA
- US status
- approved
- Patents linked
- 0
- News articles
- 0
Quick answer
donanemab-azbt (KISUNLA) is an FDA-listed pharmaceutical active ingredient. Route of administration: injection. Current US regulatory status: approved.
Key facts
INN donanemab-azbt
Brand KISUNLA
Route INJECTION
Formulation INJECTABLE
Frequently asked questions
What is donanemab-azbt?
donanemab-azbt (KISUNLA) is an FDA-listed pharmaceutical active ingredient. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for donanemab-azbt?
KISUNLA is a marketed brand name for donanemab-azbt. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of donanemab-azbt?
donanemab-azbt has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.